0001032210-01-501243.txt : 20011031 0001032210-01-501243.hdr.sgml : 20011031 ACCESSION NUMBER: 0001032210-01-501243 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20011001 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20011029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TARGETED GENETICS CORP /WA/ CENTRAL INDEX KEY: 0000921114 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911549568 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23930 FILM NUMBER: 1769085 BUSINESS ADDRESS: STREET 1: 1100 OLIVE WAY STREET 2: STE 100 CITY: SEATTLE STATE: WA ZIP: 98101 BUSINESS PHONE: 2066237612 MAIL ADDRESS: STREET 1: 1100 OLIVE WAY STREET 2: STE 100 CITY: SEATTLE STATE: WA ZIP: 98101 8-K 1 d8k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------------------- Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 1, 2001 (Date of Report) (Date of Earliest Event Reported) TARGETED GENETICS CORPORATION (Exact Name of Registrant as Specified in Charter) Washington 0-23930 91-1549568 (State or Other Jurisdiction (Commission File No.) (IRS Employer of Incorporation) Identification No.) 1100 Olive Way, Suite 100, Seattle, WA 98101 (Address of Principal Executive Offices, including Zip Code) (206) 623-7612 (Registrant's Telephone Number, Including Area Code) None (Former Name or Former Address, if Changed Since Last Report) Item 5. Other Events. On October 1, 2001, Targeted Genetics Corporation announced the appointment of Todd E. Simpson to the position of Vice President, Finance and Administration, and Chief Financial Officer. A copy of the press release issued by Targeted Genetics on October 1, 2001, announcing this appointment is attached as Exhibit 99.1 and is incorporated into this current report by reference. Item 7. Financial Statements and Exhibits. (c) Exhibits. 99.1 Press Release of Targeted Genetics Corporation dated October 1, 2001. 99.2 Form of Senior Management Employment Agreement between Targeted Genetics Corporation and its Executive Officers, incorporated by reference to Exhibit 10.2 to Targeted Genetics' annual report on Form 10-K for the year ended December 31, 1996, filed with the SEC on March 17, 1997. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TARGETED GENETICS CORPORATION Date: October 26, 2001 By: /s/ H. Stewart Parker ------------------------------------- H. Stewart Parker President and Chief Executive Officer INDEX TO EXHIBITS Exhibit Number Description ------- ----------- 99.1 Press Release of Targeted Genetics Corporation dated October 1, 2001. 99.2 Form of Senior Management Employment Agreement between Targeted Genetics Corporation and its Executive Officers, incorporated by reference to Exhibit 10.2 to Targeted Genetics' annual report on Form 10-K for the year ended December 31, 1996, filed with the SEC on March 17, 1997. EX-99.1 3 dex991.txt PRESS RELEASE DATED 10/01/2001 Exhibit 99.1 Monday October 1, 8:30 am Eastern Time Press Release SOURCE: Targeted Genetics Corporation Targeted Genetics Appoints Chief Financial Officer SEATTLE, Oct. 1 /PRNewswire/ -- Targeted Genetics Corporation (Nasdaq: TGEN - news) today announced the appointment of Todd E. Simpson to the position of Vice President, Finance and Administration, and Chief Financial Officer. Mr. Simpson brings 18 years of financial management experience to the Company. Mr. Simpson most recently served as Vice President, Finance & Administration and Chief Financial Officer of Aastrom Biosciences, Inc., a publicly held cell therapy company. At Aastrom, he led the completion of numerous public and private financings totaling nearly $70 million and was instrumental in the development and implementation of strategic planning as well as operations. Previously he was Vice President Finance of Telios Pharmaceuticals, Inc., a publicly held life sciences company. From 1983 to 1992 he practiced public accounting at Ernst & Young, LLP, focusing in the life sciences industry among others. He holds a B.S. in Business Administration and Computer Science from Oregon State University and is a certified public accountant. "Todd's experience and expertise in the biotech financial world will benefit Targeted Genetics significantly and made him the candidate of choice for this position," said H. Stewart Parker, the Company's President and Chief Executive Officer. "His contacts in, and understanding of, the financial community have enabled him to lead successful financing transactions, even in difficult markets. Additionally, his operations experience will be a great asset to us as we move forward with the plans for our large-scale AAV manufacturing facility in Bothell and continue to build upon our leadership position in gene therapy. I have always believed that Targeted Genetics has one of the most talented management teams in the business, and Todd is of that caliber. We all look forward to working together towards bringing new therapies to patients in need and building value for our shareholders." "I believe that Targeted Genetics is positioned for growth and I am tremendously pleased to have the opportunity to join the Company," said Mr. Simpson. "Gene therapy, already understood to hold enormous potential in the treatment of genetic diseases, is beginning to be appreciated by a broader audience as the technology is seen as a novel approach to delivering protein therapeutics. Success in this arena will require the ability to integrate genes and vectors in order to target a desired cell population and achieve a therapeutic effect. I believe that Targeted Genetics' combination of viral and non-viral delivery vectors, portfolio of genes and high-caliber partnerships and strategic relationships uniquely position the Company for success. These important assets, coupled with the Company's robust and diverse portfolio of product candidates, should enable Targeted Genetics to create additional value and further differentiate the Company as the leading gene delivery franchise." Targeted Genetics Corporation develops gene therapy products for the treatment of acquired and inherited diseases. The Company has lead clinical product development programs targeting cystic fibrosis and cancer, and a promising pipeline of product candidates focused on hemophilia A, arthritis, cancer, lysosomal storage diseases, cardiovascular disease and AIDS prophylaxis. The Company has a broad platform of gene delivery technologies and, through its majority-owned subsidiary, CellExSys, Inc., a promising body of technology for cellular therapy. For more information about Targeted Genetics Corporation and CellExSys, Inc., please visit the Company's web site at http://www.targetedgenetics.com. NOTE: This release contains forward-looking statements, which involve current expectations or forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known or unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from those expressed in the forward-looking statements for a number of reasons, including the factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2001, filed with the SEC. You should not unduly rely on these forward-looking statements, which speak only as of the date of this release. Targeted Genetics undertakes no obligation to update any forward-looking statements to reflect new information, circumstances or events after the date of this release. SOURCE: Targeted Genetics Corporation 2